Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

PURPOSE: To evaluate the safety, pharmacokinetics, and preliminary activity of bemarituzumab in patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA). PATIENTS AND METHODS: FPA144-001 was a phase I, open-label, multicenter trial consisting of the following 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Catenacci, Daniel V.T., Rasco, Drew, Lee, Jeeyun, Rha, Sun Young, Lee, Keun-Wook, Bang, Yung Jue, Bendell, Johanna, Enzinger, Peter, Marina, Neyssa, Xiang, Hong, Deng, Wei, Powers, Janine, Wainberg, Zev A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367551/
https://www.ncbi.nlm.nih.gov/pubmed/32167861
http://dx.doi.org/10.1200/JCO.19.01834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367551/
https://www.ncbi.nlm.nih.gov/pubmed/32167861
http://dx.doi.org/10.1200/JCO.19.01834

Ejemplares similares